FGF21 and Hepatic steatosis: PPARα agonists, such as bezafibrate and a novel drug MHY2013, can significantly increase the expression of FGF21 for alleviating obesity-induced insulin resistance, dyslipidemia and hepatic steatosis (An et al., 2017).